

The National Surveillance System for Hospital Health Care Workers



**Summary Report
for data collected from
June 1995 through July 1999**

NaSH Summary Report June 1995 – July 1999

Table of Contents

	<u>Page</u>
Introduction	3
Figure 1 Exposure Types for All Reported Blood Exposures.....	4
Figure 2 Work Location of Blood/ Body Fluid Exposures.....	5
Table 1 Work Location of Blood/ Body Fluid Exposures by Hospital	6
Figure 3 Occupational Groups of HCWs Exposed to Blood/ Body Fluids.....	7
Table 2 Occupational Groups of HCWs Exposed to Blood/ Body Fluids by Hospital	8
Figure 4 Device Types for Percutaneous Injuries.....	9
Table 3 Device Types for all Percutaneous Injuries by Hospital.....	10
Figure 5 Purpose of Hollow-Bore Needles Involved in Percutaneous Injuries.....	11
Table 4 Purpose of Hollow-Bore Needles Involved in Percutaneous Injuries by Hospital	12
Figure 6 Percutaneous Injuries Associated with Safety Devices	13
Figure 7 Circumstances of Injuries Involving Active Safety Devices.....	14
Figure 8 Distribution of Bloodborne Pathogen Status for 5,251 Known Source Patients.....	15
Figure 9 HCWs Tested after an Exposure to an Infected Source Patient.....	16
Table 5 HCWs with No Follow-up Testing after Exposure to a Source Patient Infected with HIV by Hospital.....	17
Table 6 HCWs with No Follow-up Testing after Exposure to a Source Patient Infected with HCV By Hospital.....	18
Figure 10 PEP Use after Occupational Exposure to Known Source Patients by Source Patient Serostatus	19
after June 30, 1996	
Figure 11 Use of HIV PEP Drugs July 1996 - June 1999	20
Table 7 Reasons for not Completing PEP	21
Table 8 PEP Toxicity	22
Table 9 Rates of Needlestick Injury Reporting by Occupation, 1998.....	23
Table 10 Rates of Needlestick Injury Reporting by Hospital, 1998.....	24
Table 11 HCW Immune Status for Hepatitis B Vaccine by Hospital.....	25
Table 12 Two-step TSTs by Hospital	26
Table 13 Exposures to Vaccine Preventable Diseases	27
Table 14 HCW Immune Status for Vaccine Preventable Diseases by Hospital - Measles	28
Table 15 HCW Immune Status for Vaccine Preventable Diseases by Hospital- Mumps.....	29
Table 16 HCW Immune Status for Vaccine Preventable Diseases by Hospital- Rubella	30
Table 17 HCW Immune Status for Vaccine Preventable Diseases by Hospital- Varicella.....	31


INTRODUCTION

The tables and figures in this report provide the reader with an understanding of the ability of the NaSH project to describe a variety of occupational health issues within hospitals. This report provides no inferential analysis regarding the differences noted between and within hospitals. These data summarize all exposures reported to the CDC from June 1995, when the NaSH project began, through July 1999, unless otherwise noted.

On selected tables in the report, each participating hospital which submitted data in time to be included in the report is described with a five digit number. These numbers were randomly assigned to each NaSH hospital by the CDC, and each participating hospital is provided with their random number upon request. In this way, each hospital will know which number identifies their hospital, but will be blinded to the identity of other participating hospitals. As the number of participating hospitals increases in the future, comparative tables from different regions of the U.S. will be included so that hospitals may perform regional comparisons.

The next NaSH report will also include data regarding rates of injuries and exposure events, which will allow hospitals to “benchmark” their hospital for selected rates.

**Figure 1. Exposure Types for
All Reported Exposures
(n=5,520)**



**Figure 2. Work Locations of Blood/Body Fluid Exposures
(n=5,520)**




Table 1

Work Locations of Blood/Body Fluid Exposures (n=5,520)											
Hospital	In Patient	OR/Procedure Rooms	ICU	ER	Outpatient	Laboratories	Waste/ Laundry/Supply	Other	Missing	All	Total
92326	26%	34%	15%	9%	7%	4%	1%	4%	1%	13%	712
64873	20%	21%	8%	8%	12%	11%	2%	17%	0%	2%	123
53424	22%	15%	6%	3%	22%	4%	<1%	28%	0%	5%	267
79449	40%	21%	12%	10%	4%	3%	1%	9%	0%	5%	225
67640	21%	44%	17%	3%	6%	6%	1%	2%	0%	12%	623
92772	42%	31%	12%	5%	3%	6%	1%	1%	0%	2%	127
34550	39%	27%	13%	3%	8%	5%	1%	4%	0%	7%	394
56294	53%	22%	4%	1%	9%	8%	1%	2%	0%	3%	154
69602	37%	40%	3%	7%	13%	0%	0%	0%	0%	1%	30
46529	35%	21%	28%	7%	2%	2%	4%	1%	0%	3%	170
49144	34%	20%	22%	8%	13%	2%	1%	0%	0%	2%	87
39169	31%	33%	14%	9%	8%	4%	0%	1%	0%	4%	213
60257	38%	32%	10%	7%	9%	3%	<1%	1%	0%	11%	578
18451	35%	26%	10%	11%	11%	6%	1%	1%	0%	9%	478
88011	37%	34%	16%	6%	5%	2%	0%	1%	0%	2%	89
44720	21%	34%	3%	19%	10%	4%	1%	8%	0%	4%	209
30360	21%	29%	18%	12%	12%	6%	2%	<1%	0%	6%	313
58025	43%	23%	14%	9%	2%	8%	1%	1%	1%	6%	345
35441	28%	34%	10%	7%	9%	4%	1%	7%	0%	2%	129
84568	29%	24%	24%	4%	13%	1%	4%	3%	0%	1%	80
47990	0%	0%	20%	0%	20%	60%	0%	0%	0%	<1%	5
50981	20%	20%	27%	7%	20%	7%	0%	0%	0%	<1%	15
76167	36%	21%	0%	21%	0%	0%	0%	21%	0%	<1%	14

Figure 3. Occupational Groups of HCWs Exposed to Blood/Body Fluids (n=5,520)




Table 2**Occupational Groups of HCWs Exposed to Blood/Body Fluids by Hospital**

(n=5,520)

Hospital	Nurse	Physician	Technician	House/Maint	Students	Clerical/Admin	Research	Dental	Other	All
92326	47%	26%	14%	4%	2%	2%	<1%	<1%	4%	785
64873	55%	6%	28%	7%	0%	<1%	0%	0%	3%	123
53424	27%	37%	6%	2%	17%	0%	2%	8%	2%	267
79449	30%	46%	11%	5%	<1%	3%	0%	<1%	5%	225
67640	43%	36%	13%	4%	0%	<1%	1%	0%	2%	623
92772	59%	2%	30%	6%	0%	0%	0%	0%	3%	127
34550	51%	21%	14%	1%	8%	<1%	<1%	3%	1%	394
56294	54%	12%	6%	7%	<1%	3%	10%	0%	8%	154
69602	67%	3%	30%	0%	0%	0%	0%	0%	0%	30
46529	48%	17%	21%	11%	2%	0%	0%	0%	1%	170
49144	54%	13%	13%	3%	6%	0%	0%	1%	10%	87
39169	47%	26%	15%	2%	4%	0%	<1%	2%	4%	213
60257	47%	28%	12%	3%	5%	<1%	<1%	0%	4%	578
18451	34%	42%	9%	2%	2%	<1%	<1%	<1%	9%	478
88011	43%	22%	15%	3%	0%	2%	0%	0%	15%	89
44720	24%	38%	11%	0%	11%	<1%	10%	<1%	13%	209
30360	38%	44%	12%	4%	0%	<1%	<1%	0%	<1%	313
58025	48%	31%	13%	3%	0%	2%	2%	0%	2%	412
35441	30%	33%	16%	5%	6%	0%	2%	5%	4%	129
84568	59%	15%	6%	3%	3%	0%	13%	3%	0%	80
47990	0%	60%	0%	0%	40%	0%	0%	0%	0%	5
50981	27%	47%	0%	7%	7%	0%	0%	0%	13%	15
76167	50%	7%	14%	0%	0%	0%	0%	0%	29%	14

Figure 4. Device Types for Percutaneous Injuries (n=4,569)




Table 3

Device Types for all Percutaneous Injuries by Hospital (n=4,569)												
Hospital	Syringe	Butterfly	IV stylet	Vacuum	Other HB	Suture	Scalpel	Lancet	Glass	Other	Unknown	Total
92326	32%	14%	5%	1%	4%	17%	7%	5%	2%	14%	0%	633
64873	31%	4%	1%	2%	19%	8%	6%	4%	2%	23%	1%	107
53424	40%	9%	1%	<1%	3%	16%	11%	4%	1%	16%	0%	232
79449	21%	10%	3%	8%	13%	14%	10%	5%	2%	14%	0%	175
67640	32%	5%	2%	2%	10%	25%	8%	1%	2%	12%	<1%	484
92772	17%	4%	15%	20%	11%	8%	6%	5%	1%	13%	0%	112
34550	45%	8%	8%	1%	5%	10%	6%	5%	1%	14%	0%	345
56294	67%	8%	1%	4%	2%	11%	3%	0%	1%	3%	0%	145
69602	68%	0%	14%	0%	0%	11%	4%	0%	4%	0%	0%	28
46529	36%	18%	5%	3%	2%	11%	6%	10%	2%	10%	0%	149
49144	33%	14%	16%	4%	3%	10%	9%	1%	1%	7%	0%	69
39169	26%	15%	6%	4%	6%	23%	7%	3%	3%	7%	0%	178
60257	25%	30%	8%	2%	5%	14%	6%	1%	1%	8%	0%	510
18451	33%	22%	8%	3%	6%	15%	4%	1%	2%	6%	0%	401
88011	13%	19%	19%	4%	11%	13%	9%	0%	5%	8%	0%	79
44720	28%	10%	5%	4%	1%	28%	4%	1%	2%	17%	0%	145
30360	32%	9%	4%	4%	8%	22%	9%	1%	2%	9%	0%	254
58025	34%	13%	8%	5%	9%	9%	7%	1%	2%	11%	0%	330
35441	32%	6%	5%	5%	5%	15%	11%	5%	1%	14%	0%	110
84568	45%	2%	0%	16%	2%	14%	2%	2%	0%	19%	0%	58
47990	33%	0%	0%	33%	0%	0%	33%	0%	0%	0%	0%	3
50981	7%	14%	0%	7%	14%	29%	14%	7%	0%	0%	7%	14
76167	38%	0%	0%	0%	13%	13%	0%	13%	0%	25%	0%	8

Figure 5. Purpose of Hollow-Bore Needles Involved in Percutaneous Injuries (n=2,826)





Table 4

Purpose of Hollow-Bore Needles Involved in Percutaneous Injuries by Hospital (n=2,826)										
Hospital	Phlebotomy	IM/Subq Injection	Insert IV Line (peripheral or central)	Manipulate IV Line	Other Blood Sample	Blood Sample Obtained via Line	Transferring	Other	Unknown	All
92326	24%	33%	12%	6%	4%	2%	1%	9%	10%	351
64873	17%	0%	15%	20%	2%	0%	3%	17%	27%	60
53424	26%	29%	13%	11%	6%	0%	4%	9%	2%	122
79449	23%	7%	10%	24%	13%	1%	3%	7%	11%	97
67640	15%	24%	12%	12%	4%	4%	3%	14%	13%	250
92772	29%	5%	24%	7%	11%	0%	7%	8%	9%	75
34550	12%	13%	13%	40%	3%	3%	2%	3%	11%	231
56294	8%	8%	16%	40%	3%	0%	1%	8%	17%	119
69602	26%	30%	17%	13%	0%	4%	0%	9%	0%	23
46529	28%	11%	9%	25%	6%	3%	6%	2%	8%	96
49144	29%	12%	27%	8%	0%	10%	0%	8%	6%	49
39169	36%	23%	14%	3%	8%	0%	3%	5%	8%	100
60257	42%	13%	12%	10%	5%	3%	1%	5%	10%	358
18451	33%	16%	15%	7%	9%	3%	2%	9%	6%	292
88011	31%	4%	21%	12%	4%	0%	0%	15%	13%	52
44720	25%	28%	10%	10%	7%	4%	3%	4%	9%	69
30360	26%	23%	10%	9%	10%	3%	3%	13%	3%	145
58025	17%	20%	20%	16%	9%	5%	2%	6%	6%	229
35441	19%	20%	17%	7%	8%	2%	2%	17%	8%	59
84568	38%	19%	0%	14%	14%	5%	3%	3%	5%	37
47990	0%	0%	0%	50%	0%	0%	0%	50%	0%	2
50981	50%	0%	0%	17%	0%	0%	0%	33%	0%	6
76167	25%	25%	0%	0%	0%	0%	0%	50%	0%	4

**Figure 6. Percutaneous Injuries Associated
with Safety Devices
(n=195)**



**Figure 7. Circumstances of Injuries
Involving Active Safety Devices
(n=167)**





Figure 8. Distribution of Bloodborne Pathogen Status for 5,251 Known Source Patients



160 (3.0%) were coinfectd with HIV and HCV

Figure 9. HCWs Tested after an Exposure to an Infected Source Patient




Table 5

HCWs with No Follow-up Testing after Exposure to a Source Patient Infected with HIV by Hospital				
Hospital	Exposures to Source Patients with HIV	Number and Percentage of HCWs who did not have Follow-up Testing		
92326	63	2	3%	
64873	4	4	100%	
53424	23	22	96%	
79449	26	26	100%	
67640	20	6	30%	
92772	2	0	0%	
34550	8	0	0%	
56294	1	1	100%	
46529	3	1	33%	
49144	1	0	0%	
60257	31	15	48%	
18451	82	0	0%	
88011	2	0	0%	
44720	46	27	59%	
30360	28	5	18%	
58025	45	8	18%	
76167	2	1	50%	
TOTAL	387	118	30%	

Table 6

HCWs with No Follow-up Testing After Exposre to a Source Patient Infected with HCV				
Hospital	Exposures to Source Patients with HCV	Number and Percentage of HCWs who did not have Follow-up Testing		
92326	73	1	1%	
64873	2	2	100%	
53424	34	33	97%	
79449	20	4	20%	
67640	31	6	19%	
92772	4	0	0%	
34550	6	1	17%	
56294	2	0	0%	
46529	6	3	50%	
49144	1	0	0%	
39169	9	8	89%	
60257	78	21	27%	
18451	56	1	2%	
88011	4	0	0%	
44720	55	28	51%	
30360	15	2	13%	
58025	40	0	0%	
35441	6	6	100%	
84568	8	3	38%	
47990	1	1	100%	
50981	2	0	0%	
76167	2	0	0%	
TOTAL	455	120	26%	

Figure 10. PEP Use after Occupational Exposures to Known Source Patients by Source Patient HIV Serostatus After June 30, 1996

	Initiated PEP	Completed PEP**
HIV Positive	201/343 (59%)	86/177 (49%)
HIV Negative*	451/3059 (15%)	38/416 (9%)
Unknown/Missing	234/958 (24%)	44/180 (24%)
TOTAL	886/4360 (20%)	168/773 (22%)

* For most HIV negative source patients, the source patient serostatus was not known at the time of the exposure.

** "Completion" of PEP is those HCWs who were described by the hospital as completing PEP therapy, even though many of these HCWs did not take 28 days of PEP as recommended by CDC.

**Figure 11. Use of HIV PEP Drugs
July 1996-June 1999
(n=742)**




Table 7

Reasons for not Completing PEP

- 219 (36%) Source patient was HIV negative
- 136 (23%) Adverse signs or symptoms
- 37 (6%) HCW choice
- 23 (4%) Possible anti-retroviral resistance
- 11 (2%) Laboratory results
- 10 (2%) Lost to follow-up

Table 8

PEP Toxicity

- Of 886 HCWs who initiated PEP, 742 (84%) had a drug form completed.
- 244 HCWs reported they had symptoms; however, information on the type of symptoms was available for 149 HCWs.
- Of the 299 HCWs who had a completed follow-up form within two months, the 7 most commonly reported symptoms were nausea (31%), malaise/fatigue (29%), emotional distress(12%), headache (11%), loss of appetite (8%), diarrhea (7%), and vomiting (7%).

Table 9

Rates of Needlestick Injury Reporting by Occupation, 1998

<u>Occupational Groups</u>	<u>Reporting Rates</u>
Surgeons	27%
Other MDs	49%
Nurses	42%
Technicians	67%
Housekeepers	66%
Phlebotomists	53%
Overall	39%

Table 10

Rates of Needlestick Injury Reporting by Hospital, 1998			
Hospital	Number of Survey Respondents	Number of Respondents with at least One Injury	Reporting Rate
92326	1007	55	58%
64873	332	47	45%
79449	603	59	53%
67640	931	203	29%
92772	521	57	47%
34550	1018	130	49%
56294	1148	201	24%
60257	841	78	55%
18451	3733	124	66%
88011	1017	53	82%
30360	1156	117	42%
58025	1517	64	40%
47990	431	23	43%
		Overall Reporting Rate	42%
*Hospitals with less than 300 survey respondents were omitted from this table.			

Table 11

HCW Immune Status for Hepatitis B Virus by Hospital									
Hospital	ACIP* Immune	Self-reported Vaccination	Vaccination In Progress	Exempt	Declined	Contraindicated	Not in OSHA Risk Category	Unknown	Total
92326	62%	15%	5%	<1%	2%	0%	27%	6%	11,068
64873	38%	23%	2%	0%	35%	<1%	<1%	2%	2,036
79449	61%	4%	4%	0%	14%	0%	0%	17%	1,254
67640	74%	20%	4%	0%	1%	0%	<1%	1%	536
92772	39%	33%	6%	0%	9%	<1%	17%	3%	1,559
34550	60%	21%	6%	0%	<1%	0%	10%	9%	1,263
56294	57%	1%	4%	0%	<1%	<1%	35%	23%	2,166
69602	100%	0%	0%	0%	0%	0%	0%	0%	32
46529	61%	29%	8%	0%	<1%	0%	<1%	1%	166
49144	63%	38%	0%	0%	0%	0%	0%	0%	40
60257	35%	21%	2%	<1%	6%	<1%	27%	18%	4,089
18451	73%	<1%	3%	0%	12%	<1%	18%	8%	7,010
88011	78%	0%	5%	0%	5%	0%	28%	6%	1,862
30360	37%	18%	2%	0%	1%	0%	27%	25%	6,588
58025	59%	10%	10%	0%	10%	<1%	23%	2%	8,061
35441	81%	5%	5%	<1%	3%	0%	27%	1%	1,483
84568	24%	63%	4%	0%	4%	0%	0%	6%	72
47990	67%	23%	10%	0%	0%	0%	0%	0%	478
76167	33%	22%	4%	0%	39%	<1%	0%	2%	1,282

*A C IP Immune= documented vaccination and not vaccinated due to previous infection/immunity.

HCWs not in OSHA category were not included in the denominator

Table 12

Two-step TSTs by Hospital				
Hospital	Boosters	Negative	Uninterpretable/ Incomplete	Total
92326	9	3409	1563	4981
64873	0	36	1	37
79449	8	193	5	206
92772	1	389	30	420
56294	0	37	177	214
60257	2	81	784	867
18451	2	258	86	346
88011	5	338	25	368
30360	8	447	478	933
58025	20	1131	5	1156
35441	2	54	2	58
76167	0	10	0	10
All	57	6383	3156	9596

Table 13

Exposures to Vaccine-Preventable Diseases						
Disease	Exposure Events	HCWs Exposed	HCWs Susceptible	HCWs Evaluated	HCWs with Disease as Outcome	Work Days Lost
Varicella	60	919	26	50	5	211
Disseminated Herpes zoster	12	143	4	2	1	9
Localized Herpes zoster	6	49	2	4	0	4
Pertussis	5	98	98	65	0	0
Flu-like Illness	4	57	50	41	0	0
TOTAL	87	1266	180	162	20	224

Table 14

HCW Immunostatus for Vaccine-Preventable Diseases by Hospital						
MEASLES						
Hospital	ACIP Immune*	In Progress	Self-Reported	Other	Unknown	TOTAL
		Illness/Vaccine				
92326	99%	1%	0%	<1%	<1%	11071
64873	63%	0%	33%	0%	4%	1521
79449	96%	0%	1%	0%	3%	1254
67640	96%	0%	<1%	<1%	2%	506
92772	50%	0%	48%	0%	3%	1573
34550	61%	0%	31%	<1%	8%	1248
56294	92%	2%	<1%	<1%	5%	2238
69602	100%	0%	0%	0%	0%	32
46529	95%	0%	5%	0%	0%	167
49144	92%	0%	8%	0%	0%	24
60257	85%	<1%	13%	<1%	1%	4164
18451	98%	<1%	0%	0%	2%	7128
88011	93%	0%	0%	<1%	8%	1962
30360	63%	<1%	18%	<1%	20%	6600
58025	97%	0%	2%	0%	<1%	10525
35441	1%	0%	85%	0%	14%	1485
47990	60%	<1%	40%	0%	<1%	1225
*ACIP Immune for Measles/Mumps=Immune by Serology (S)+Immune by Documented Vaccination (DV)+Immune by Documented Illness (DI)+Born Before 1957 (BB)						
\$Hospitals with less than 10 observations were omitted from this table.						

Table 15

HCW Immunostatus for Vaccine-Preventable Diseases by Hospital						
MUMPS						
Hospital	ACIP Immune*	In Progress	Self-Reported	Other	Unknown	TOTAL
		Illness/Vaccine				
92326	87%	<1%	<1%	<1%	12%	11066
64873	54%	0%	40%	0%	6%	1341
79449	44%	0%	33%	0%	23%	1255
67640	95%	0%	2%	<1%	3%	520
92772	48%	0%	48%	0%	4%	1574
34550	61%	<1%	31%	<1%	8%	1253
56294	88%	8%	0%	0%	5%	107
69602	100%	0%	0%	0%	0%	32
46529	88%	0%	10%	0%	2%	127
49144	92%	0%	8%	0%	0%	24
60257	50%	<1%	39%	0%	11%	4151
18451	59%	<1%	<1%	0%	40%	6966
88011	69%	0%	0%	0%	31%	1670
30360	73%	0%	6%	<1%	21%	6596
58025	99%	0%	1%	<1%	<1%	7148
35441	<1%	0%	70%	0%	29%	1484
47990	60%	0%	40%	0%	0%	1223
*ACIP Immune for Measles/Mumps=Immune by Serology (S)+Immune by Documented Vaccination (DV)+Immune by Documented Illness (DI)+Born Before 1957 (BB)						
\$Hospitals with less than 10 observations were omitted from this table.						

Table 16

HCW Immunostatus for Vaccine-Preventable Diseases by Hospital						
RUBELLA						
Hospital	ACIP Immune**	In Progress	Self-Reported Illness/Vaccine	Other	Unknown	TOTAL
92326	99%	<1%	<1%	<1%	<1%	11069
64873	76%	<1%	13%	5%	6%	1575
79449	94%	<1%	1%	0%	4%	1254
67640	95%	0%	<1%	<1%	4%	507
92772	79%	0%	18%	<1%	3%	1583
34550	60%	0%	29%	<1%	10%	1242
56294	97%	1%	0%	0%	2%	2243
69602	100%	0%	0%	0%	0%	32
46529	96%	0%	4%	0%	0%	164
49144	96%	0%	4%	0%	0%	24
60257	88%	<1%	10%	<1%	2%	4158
18451	99%	<1%	0%	<1%	1%	7148
88011	98%	0%	0%	<1%	2%	2014
30360	54%	0%	6%	<1%	40%	6597
58025	98%	0%	<1%	0%	2%	10927
35441	<1%	0%	51%	<1%	48%	1484
47990	100%	0%	<1%	0%	0%	1192
**ACIP Immune for Rubella=S+DV						
\$Hospitals with less than 10 observations were omitted from this table.						

Table 17

HCW Immunostatus for Vaccine-Preventable Diseases by Hospital						
VARICELLA						
Hospital	ACIP Immune***	In Progress	Self-Reported Illness/Vaccine	Other	Unknown	TOTAL
92326	98%	<1%	<1%	<1%	1%	11069
64873	92%	0%	3%	<1%	5%	1303
79449	93%	0%	<1%	<1%	6%	1254
67640	96%	0%	1%	0%	3%	507
92772	90%	0%	<1%	0%	9%	1535
34550	94%	<1%	<1%	<1%	5%	1237
56294	98%	<1%	0%	0%	2%	2228
69602	100%	0%	0%	0%	0%	32
46529	98%	1%	1%	0%	0%	165
49144	94%	0%	0%	0%	6%	18
60257	70%	<1%	2%	0%	28%	4095
18451	97%	<1%	<1%	<1%	3%	7141
88011	95%	0%	<1%	0%	5%	2006
30360	59%	<1%	<1%	<1%	41%	6588
58025	91%	<1%	<1%	<1%	8%	10828
35441	78%	0%	9%	0%	13%	1494
47990	91%	0%	9%	0%	0%	1211
***ACIP Immune for Varicella=S+DV+DI+Self-Reported Illness (RI)						
\$Hospitals with less than 10 observations were omitted from this table.						